1	Mendelian randomisation analysis using GWAS and eQTL data to
2	investigate the relationship between chronotype and neuropsychiatric
3	disorders and their molecular basis
4	
5	Shane Crinion <sup>1</sup> , Cathy A. Wyse <sup>2</sup> , Gary Donohoe <sup>1</sup> , Lorna M. Lopez <sup>2¶</sup> , Derek W. Morris <sup>1¶</sup> *
6	
7	1. Centre for Neuroimaging, Cognition and Genomics, School of Biological and Chemical
8	Sciences and School of Psychology, University of Galway, Galway, Ireland.
9	2. Department of Biology, Maynooth University, Maynooth, Ireland.
10	
11	* Corresponding author
12	Email: derek.morris@universityofgalway.ie (DWM)
13	
14	<sup>¶</sup> These authors contributed equally to this work.
15	
16	
17	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 18 Abstract

19 A wide range of comorbidities have been observed with neuropsychiatric disorders, of which 20 sleep disturbances are one of the most common. Chronotype, a self-reported measurement of 21 an individual's preference for earlier or later sleep timing, is a proxy sleep measure that has 22 been linked to neuropsychiatric disorders (NPDs). By investigating how chronotype influences 23 risk for neuropsychiatric disorders and, vice versa, how risk for neuropsychiatric disorders 24 influences chronotype, we may identify modifiable risk factors for each phenotype. By 25 investigating the specific genetic mechanisms that are common to the risk of evening 26 chronotype and the risk of NPDs, we may gain further understanding of the relationship and 27 causal direction in these phenotypes. Here we use Mendelian randomisation (MR), a method 28 used to explore causal effects, to 1) study the causal relationships between neuropsychiatric 29 disorders and chronotype and 2) characterise the genetic components of these phenotypes. 30 Firstly, we investigated if a causal role exists between six neuropsychiatric disorders and 31 chronotype using the largest genome-wide association studies (GWAS) available. Secondly, we 32 integrated data from expression quantitative trait loci (eQTLs) to investigate the role of gene 33 expression alterations on these phenotypes. We also used colocalization to validate that the 34 same variant is causal for gene expression and each outcome. We identified that the evening 35 chronotype is causal for increased risk of schizophrenia and autism spectrum disorder and, in 36 the opposite direction, that insomnia and schizophrenia are causal for a tendency towards 37 evening chronotype. We identified twelve eQTLs where gene expression changes in brain or 38 blood were causal for one of the tested phenotypes (bipolar disorder, chronotype and 39 schizophrenia). These findings provide important evidence for the complex, bidirectional 40 relationship that exists between these sleep and neuropsychiatric disorders, and use gene 41 expression data to identify causal roles for genes at associated loci.

42

# 43 Author Summary

44 Sleep disturbances are commonly observed features of neuropsychiatric disorders. Chronotype, 45 a behavioural manifestation of an individual's preference for early or late sleep timing i.e. 46 morning chronotype means a preference for earlier sleep and wake times, has been used as a 47 behavioural marker of underlying circadian function. Here, we used data from the largest 48 genetic studies available to test the causal relationship between chronotype and risk for 49 neuropsychiatric disorders. We found that individuals with the evening chronotype have greater 50 risk for schizophrenia or autism spectrum disorder. In the other direction, we found insomnia or 51 schizophrenia diagnosis is causal for a tendency towards evening chronotype. We searched for 52 DNA variants that influence chronotype or risk for neuropsychiatric disorders through alterations 53 of gene expression in blood and brain tissues. We found twelve DNA variants with a significant 54 effect on chronotype or risk of either bipolar disorder or schizophrenia. These results 55 demonstrate that sleep and neuropsychiatric disorders have a complex bidirectional relationship 56 and that the causal role of some genes is due to variants that alter gene expression.

# 58 Introduction

59 Neuropsychiatric disorders include the adult-onset disorders of bipolar disorder (BD), major 60 depressive disorder (MDD) and schizophrenia (SZ), and the child-onset conditions of attention 61 deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). These disorders are 62 multifactorial, caused by polygenic inheritance of many genetic variants in combination with 63 various environmental factors (1). Symptoms of NPD are varied and include changes in 64 behaviour, brain function and cognition, that can be episodic or continuous and range from mild 65 to severe. Diagnosis of NPD is based on clinical evaluation of highly variable changes in 66 behaviour and the heterogeneous nature of these disorders along with the significant overlap 67 between diagnoses makes the identification of risk factors and molecular mechanisms difficult.

68

69 Sleep-related disorders are one of the most common comorbidities with neuropsychiatric 70 disorders and typically individuals with a neuropsychiatric diagnosis experience some degree of 71 difficulty sleeping (2). Insomnia is classed as a neuropsychiatric disorder and a sleep disorder 72 and is one of the most common comorbidities of each neuropsychiatric disorder listed above (3). 73 Evidence from genetic studies support an association between chronotype and changes in risk 74 for neuropsychiatric disorders (4). Chronotype is a behavioural manifestation of an individual's 75 underlying circadian rhythm e.g. having the morning chronotype means having a preference to 76 wake up and go to sleep earlier in the 24 hour day while having the evening chronotype means 77 to prefer to wake up and go to sleep later.

78

It is often time-consuming, expensive or unethical to conduct randomised controlled trials (RCT) that could estimate the causal role of risk factors for neuropsychiatric disorders. An RCT cannot be used to investigate the causal relationship between sleep disorders and NPD, as patients could not be randomly allocated to sleep disruption groups. In such cases, Mendelian

randomisation (MR) is a powerful complementary approach that can be applied to estimate the causal effect of an exposure on an outcome using instrumental variants (IVs) (5). For example, genome-wide significant (GWS) SNPs for chronotype can be used as IVs to estimate the causal effect of chronotype (exposure) on risk for a neuropsychiatric disorder (outcome). MR can be applied bidirectionally, i.e., using GWS SNPs for neuropsychiatric disorders to estimate the causal effect of neuropsychiatric disorders on chronotype.

89

90 To investigate the complex relationship between sleep and risk for neuropsychiatric disorders, 91 we apply MR here to investigate the role of the modifiable risk factor chronotype in risk for 92 neuropsychiatric disorders and predict the contribution of the genetic component to lifetime risk 93 for both phenotypes on each other. MR studies have identified a causal relationship between 94 four neuropsychiatric disorders (ADHD, BD, MDD and SZ) and sleep-related phenotypes (3, 6, 95 7, 8) and, in the opposite direction, a causal relationship between five sleep-related phenotypes 96 (daytime napping, insomnia, morning person, long sleep duration and sleep duration) and 97 changes in risk for neuropsychiatric disorders (3, 4, 6, 7). Our study here builds on previous 98 work by using the largest GWAS available to date to explore causal relationships between 99 chronotype and neuropsychiatric disorders. Our study also implements the new MR Pleiotropy 100 RESidual Sum and Outlier (MR-PRESSO) method, which uses simulation to detect and remove 101 horizontal pleiotropy (9). This may identify new causal associations or provide additional 102 evidence for the chronotype-neuropsychiatric disorder relationship.

103

MR analysis can be extended to study the biological mechanisms that are individually involved in chronotype and risk for neuropsychiatric disorders. In this approach, expression quantitative trait loci (eQTLs) are used as IVs to estimate the causal effect of gene expression (exposure) on genetically-based outcomes, e.g., eQTLs are used to estimate the causative effect of changes in gene expression (exposure) on risk for a neuropsychiatric disorder or chronotype (outcome).

MR and colocalization are used together as an approach to provide evidence for the association between a genetic variant and disease risk (10). Previously this method has been implemented to link changes in gene expression to psychiatric and neurodevelopmental disorders and identify potential drug targets (11).

113

114

115 Overall, this study had two major objectives. The first was to investigate the causal relationship 116 between chronotype and neuropsychiatric disorders using MR with GWAS summary statistics. 117 To do this we used GWAS-based IVs associated with chronotype to investigate its effect on risk 118 of neuropsychiatric disorders (ADHD, ASD, BD, MDD, Insomnia and SZ) and we used GWAS-119 based IVs associated with neuropsychiatric disorders to investigate their effect on chronotype. 120 The second objective was to investigate the causal relationship between genetic variants 121 associated with changes in gene expression and chronotype and/or neuropsychiatric disorders 122 using MR with eQTL and GWAS summary statistics. The eQTL data employed was from 123 PsychENCODE (http://resource.psychencode.org/) and GTEx (https://gtexportal.org/home/) for 124 a range of brain tissues (hippocampus, hypothalamus and prefrontal cortex) plus whole blood. 125

### 127 Materials & Methods

128 These methods follow the guidelines outlined in Strengthening the Reporting of Observational 129 Studies in Epidemiology using Mendelian Randomization (STROBE)-MR which was developed 130 to assist researchers to report MR studies in a clear and transparent way (12). STROBE-MR 131 provides guidelines to improve the quality and assessment of MR studies. The checklist 132 includes 20 items, of which the first three items have been addressed in the Title and 133 Introduction of this manuscript (1: indicating MR as the study design, 2: explaining the scientific 134 background and rationale of the study and justifying use of MR, and 3: stating specific 135 objectives). The remaining items are addressed in the Materials and Methods (items 4-9), 136 Results (items 10-13) and Discussion (items 14-20). The complete checklist and the relevant 137 text from the manuscript for each point is outlined in Supplementary Table 1 (for first objective; 138 bi-directional MR study of chronotype and neuropsychiatric disorders) and Supplementary Table 139 2 (for second objective: MR study of changes in gene expression on chronotype and risk of 140 neuropsychiatric disorders). The tables highlight the implementation of the STROBE-MR 141 guidelines throughout the manuscript.

142

# 143 Objective 1: Bi-directional two-sample MR analysis of chronotype and neuropsychiatric 144 disorders

To investigate causal relationships between neuropsychiatric disorders and chronotype, we performed a bi-directional two-sample MR analysis using genetic variants for each trait from GWAS data. We obtained summary statistics from the Psychiatric Genomics Consortium (PGC) for six neuropsychiatric disorders (ADHD, ASD, BD, MDD, Insomnia and SZ) (3, 7, 13, 14, 15, 16) and from the UK Biobank for chronotype (4). Chronotype was selected due to it being the sleep-related phenotype that has been subjected to the largest GWAS in terms of sample size

and statistical power to detect associations of small effect. A description of the GWAS data used
for neuropsychiatric disorders and chronotype is available in <u>Supplementary Table 3</u>.

153

154 To maximise power, we used the largest GWAS available for each phenotype. For each 155 neuropsychiatric disorder, the individuals were classified as cases and controls based on the 156 reported diagnoses in each GWAS. To prevent bias due to variation in the underlying sample 157 population, all individuals included in these GWAS were of European ancestry. For SZ, the 158 PGC had performed a multi-ancestry integration analysis (80% European + 20% East Asian; 159 14) so we obtained summary statistics for an entirely European ancestry sample. To avoid 160 sample overlap, GWAS summary statistics that excluded UK Biobank samples were used, when 161 available. Data for 403,195 participants was available from the UK Biobank for the morning 162 chronotype. The measurement of chronotype refers to self-reported "morning person" as 163 identified through the UK Biobank (n=449,734). A case for the morning person chronotype is a 164 participant who, for the question "Do you consider yourself to be.", answered "Definitely a morning person" or "More a morning than an evening person" whereas a control is a participant 165 166 who answered with "Definitely an 'evening' person" and "More an 'evening' than a 'morning' 167 person" in the UK Biobank data (4). All included studies reported a SNP as GWS if it reached the significance threshold ( $p < 5x10^{-8}$ ) and each study performed LD clumping on results to 168 169 identify independent GWS loci ( $r^2 < 0.1$ ). The range of clumping distance between SNPs in each 170 of the selected GWAS ranged from 250 - 3,000 kb (Supplementary Table 3).

171

During MR analysis we used genetic variants as a proxy for a trait and therefore it is important to ensure that the selected IVs are high quality and can accurately predict causality. There are three core IV assumptions that generally must hold in order for the MR study to be valid: 1) IVs are robustly associated with the risk factor; the relevance assumption. 2) IVs are not associated with any confounders; the independence assumption. 3) IVs have no association with the

177 outcome that is not mediated through the risk factor; the exclusion restriction assumption (17).

178 We address the relevance assumption by only using genetic instruments that were identified as

179 GWS loci for each phenotype, providing evidence of a strong association with the phenotype.

- 180
- 181

182 We address the independence and exclusion restriction assumptions by using several MR 183 methods to estimate causal effect and correct for bias due to horizontal pleiotropy. Inverse-184 variance weighted (IVW) meta-analysis was selected as the primary analysis for causal 185 estimate due to its ability to provide maximum power possible. This method combines effect estimates for all genetic instruments to provide the greatest valid causal estimates, under the 186 187 assumption of balanced pleiotropy (17). IVW MR was implemented using the mr ivw function 188 from the TwoSampleMR R package on the default settings (18). By default, the IVW random-189 effects model is performed, allowing overdispersion in the weighted linear regression (the 190 residual standard error is not fixed to be one, but is not allowed to take values below one). We 191 also selected that a minimum of four IVs were required to ensure a robust causal estimate was 192 being produced in the MR model. We utilised the MR-PRESSO test to identify and remove 193 outliers via a simulation approach that uses observed and expected distributions of tested 194 variants to detect horizontal pleiotropy (9).

195

We additionally used the MR-PRESSO global test, which detects bias among all IVs by comparing the observed distance of all variants to the regression line, to detect horizontal pleiotropy and the MR-PRESSO distortion test to test for significant distortion before correction (9). These functions were implemented using the mr\_presso function from the R package MRPRESSO. We also implemented a Bonferroni significance threshold to correct for multipletesting (i.e., P < 0.05/12 tests for bidirectional analysis of 6 phenotypes).

9

203 Causal estimates were also made using MR-Egger regression (19), which corrects for average pleiotropic effects, and median-based estimate (20), which assumes >50% of instruments are 204 205 valid. The effect estimates from these methods were compared to results from IVW. The MR-206 Egger intercept test was also used to estimate bias caused by horizontal pleiotropy (19). 207 Heterogeneity was also measured using Cochran's Q statistic (21). The additional MR methods 208 were also implemented using the TwoSampleMR R package on the default settings. A number 209 of plots were also generated to evaluate the degree of causal effects and identify bias. Forest 210 plots were generated to visualise and compare causal odds ratio estimates and confidence 211 intervals for each exposure and outcome pair identified. Scatter plots were also generated 212 which plots the SNP-outcome association against the SNP-exposure association to visualise the 213 causal estimate obtained from the MR analysis (22).

214

215 We extended the analysis to examine multiple exposures concurrently to further evaluate the 216 degree of bias that may be introduced in causal estimates due to genetically similar phenotypes. 217 We performed a multi-trait MR, which is implemented to correct when IVs for exposure 1 ( $E_1$ ) 218 also have a significant effect on additional exposures ( $E_2 \rightarrow E_n$ ). The IVs for  $E_1$  are selected and 219 the effect estimates are extracted for these IVs from  $E_n$  and integrated into the MR model. Due 220 to prior knowledge of the significant genetic similarities between the psychiatric disorders (e.g. 221 BD, MDD and SZ) (23), we employed multi-trait MR to investigate the effect of bias due to 222 genetic similarities on each psychiatric disorder. We assessed the role of psychiatric disorders 223 (SZ, BD and MDD) on chronotype by performing three multi-trait MR analyses, to assess each 224 psychiatric disorder assigned as E<sub>1</sub> and extract the corresponding IVs to test the effect on 225 chronotype, i.e., MR analysis to investigate the effect of schizophrenia ( $E_1=SZ$ ,  $E_2=BD$  and 226 E<sub>3</sub>=MDD) on chronotype. We did not perform multi-trait MR for ADHD and ASD due to the low 227 number of instrumental variants available for analyses. This was also implemented using the 228 MR-PRESSO R package (9). We also utilised results from genetic correlation studies,

generated using GWASatlas, to assess the direction of effect and to compare to results fromMR (24).

231

We performed the MR analysis using the R version 4.0.2 (The R Foundation of Statistical Computing). The software used to perform this MR analysis was the R packages TwoSampleMR (<u>https://github.com/MRCIEU/TwoSampleMR</u>) and MR-PRESSO (<u>https://github.com/rondolab/MR-PRESSO</u>) and all plots were generated using the R packages ggplot2 (<u>https://ggplot2.tidyverse.org/</u>) and TwoSampleMR.

237

# 238 Objective 2: MR analysis to assess the role of SNPs associated with changes in gene 239 expression as risk factors for neuropsychiatric disorders and chronotype

240

241 This analysis uses MR to identify gene expression alterations that contribute to chronotype 242 and/or neuropsychiatric disorders. This analysis was unidirectional and investigated the effect of 243 gene expression (exposure) on neuropsychiatric disorders and chronotype (outcome) by 244 integrating eQTL data with GWAS data within a MR framework to investigate the genetic basis 245 of both neuropsychiatric disorders and chronotype, including overlap between them. Each 246 phenotype was investigated separately with the aim of contributing to current knowledge on the 247 genetic basis of each phenotype, validating previous findings from GWAS and other genomic 248 analysis methods, and/or finding previously unidentified variants or genes that link 249 neuropsychiatric disorders and chronotype.

250

To strengthen the evidence of a causal relationship, we followed up the MR analysis by performing colocalization on the top findings. MR and colocalization can be used together to validate that the variant in a genomic region has been identified as causal for both the exposure and the outcome through MR. In this analysis, MR assessed the association of an exposure

(eQTLs) with an outcome (neuropsychiatric disorders and/or chronotype). Evidence of an association indicated that the eQTLs were causal for gene expression alterations that contribute to the outcome phenotype. Colocalization was then performed where strong evidence for an association between an exposure and outcome is found through MR and assessed whether each is caused by the same or distinct variants (10). This analysis was motivated by the approach taken by Baird et al. (2021) to perform two-sample MR using eQTLs as instruments to predict effects on neuro-phenotypes (11)

262

263 We used eQTL summary statistics from blood and the brain. We selected brain regions based 264 on their relevance in the context of neuropsychiatric disorders and sleep phenotypes such as a 265 overlapping relevance to both phenotypes (Supplementary Table 4). Prefrontal cortex data from 266 PsychENCODE data was included as the largest dataset of brain eQTLs available (n=1387), 267 while GTEx whole blood was included as the largest dataset of eQTLs from GTEx (n=670) and 268 as a proxy for brain tissue. The specific brain regions that were selected were based on their 269 relevance to neuropsychiatric disorders, circadian rhythm or both and these were cortex 270 (n=205), hippocampus (n=165) and hypothalamus (n=170).

271

272 For each of the selected tissues, we obtained gene expression data from cis-eQTL summary 273 statistics provided by the Genotype-Tissue Expression (GTEx) project version 8 274 (https://gtexportal.org/) (25) and the PsychENCODE consortium 275 (https://psychencode.synapse.org/) (26). The number of samples per tissue is outlined in 276 Supplementary Table 4 and ranged from 165 samples (GTEx, hippocampus) to 1,387 samples 277 (PsychENCODE, prefrontal cortex). Information on the measurement, QC and selection of 278 genetic variants is available in the respective studies.

279

Study participants were primarily of European ancestry. eQTL summary statistics from PsychENCODE were generated using data from samples of European ancestry. eQTL summary statistics from GTEx consisted of 84.6% white, 12.9% African American and 1.3% Asian participants.

284

285 Similar to the first analysis, we used the beta coefficient to report the strength of the effect of the 286 exposure (gene expression from eQTL summary statistics) on each of the seven outcomes (six 287 neuropsychiatric disorders and chronotype) individually. The IVs for gene expression were selected by using a statistical significance threshold of  $p < 5 \times 10^{-8}$  and LD clumping was 288 289 performed by the clump\_data function from the TwoSampleMR R package on the default 290 settings, to obtain a set of independent eQTL instruments. SNPs were also filtered to include only those available in the 1000 Genomes EUR population with  $r^2 > 0.001$  and all SNPs within 291 292 clumping distance of 10,000kb window of the top hit were removed. This resulted in a total of 293 4,374 unique SNPs and 6,315 genes to study using MR analysis (Supplementary Table 4). As 294 in our first analysis, we implemented the MR analyses using the TwoSampleMR R package, 295 using the mr\_wald\_ratio function.

296

297 The causal estimate was obtained using the single instrument Wald ratio, that divides the gene-298 outcome association by the gene-exposure association (27). Similarly to the analysis performed 299 using the SMR package, developed by Zhu et al. (2016), we apply MR to assess gene 300 expression on complex traits and exploit the Wald ratio in conjunction with a colocalization 301 method (28). Colocalization analysis was performed to support evidence from MR where a 302 statistically significant causal effect was found between an eQTL and a neuropsychiatric 303 disorder and/or chronotype. Colocalization analysis validates that the same eQTLs are causal 304 for changes in gene expression and the neuropsychiatric disorder and/or chronotype. A non-305 zero result from colocalization analysis indicates that the same variants are causal in both

306 GWASs and eQTL studies, due to either causality or pleiotropy. We performed colocalization 307 using the coloc.abf function from the coloc R package (29). This function calculates posterior 308 probabilities (PP) using Bayes factors to assess the association of a SNP with two traits and 309 calculates a PP for four hypotheses, of which hypothesis 4 (PP4) > 0.7 is considered evidence 310 that a common causal variant is found between the two traits. We also undertook to validate the 311 IV assumptions by only using eQTL instruments found to have a strong effect on the exposure, 312 based on the statistical significance threshold of P-value <  $5x10^{-8}$ .

313

We calculated a beta effect size, standard error and p-value from each Wald test to test the null hypothesis that gene expression alterations were not correlated with risk of neuropsychiatric disorders and/or chronotype. The test for causal effect from MR analysis showed a statistically significant association if the statistical result passed the Bonferroni correction threshold of p < 0.05/7 (correcting for testing of six neuropsychiatric disorders plus chronotype).

319

# 321 Results

# 322 Bi-directional two-sample MR analysis of chronotype and neuropsychiatric 323 disorders

324

### 325 Causal effects of chronotype on neuropsychiatric disorders

Our two-sample MR analysis demonstrated that the morning chronotype is causal for lower risk of two neuropsychiatric disorders (**Figure 1**). This includes an association between morning chronotype and reduced risk for ASD (OR = 0.88, CI = 0.82-0.94, IVW P =  $4.37 \times 10^{-4}$ ) and reduced risk for schizophrenia (OR = 0.91, CI = 0.95-0.97, IVW P =  $2.19 \times 10^{-3}$ ). We also detected an association between morning chronotype and reduced risk for MDD (OR = 0.95, CI = 0.91-0.99, IVW P =  $1.53 \times 10^{-2}$ ), however the estimate was not statistically significant after correcting for multiple tests (Supplementary Table 5).

333

334 To investigate the accuracy of the MR IVW method for causal effect estimates, a series of 335 additional MR analyses were performed. We calculated causal effect estimates using MR-336 PRESSO, MR Egger and the median-based MR estimates and by comparing across methods. 337 we found similar beta effect sizes albeit with wider confidence intervals (Supplementary Table 338 5). Figure 2 shows that there is consistency across numerous MR methods in terms of effect 339 size and direction for the two statistically significant results. ASD (Figure 2a) and SZ (Figure 340 2b). We also performed IV outlier removal by using the MR-PRESSO outlier test which 341 determines which IVs may be confounding results by a simulation approach. The results 342 indicated that 27 outliers for SZ and no outliers for ASD were observed and subsequently these 343 were removed from the MR analysis, resulting in stronger associations identified between the 344 significant exposure-outcome pairs.

345

346				
347				
348				
	Outcome	<b>IV</b> s	OR (95% CI)	P value
	ADHD	276		0.132
			I.	
	ASD	288	<b>_</b>	0.000437
	BD	311		0.313
			I	
	Insomnia	275		0.191
	MDD	319	<b>_</b> _	0.0153
			I.	
	Schizonhrenia	294	I	0.002
	Gomeophionia	204		U.UUL
	0.520 - 0.540 - 1.600 - 1.080		0.0 0.7 1.0 1.1	-0.250 $0.276$ $1.090$ $1.$

Figure 1. MR forest plot of chronotype (exposure) vs. neuropsychiatric disorder (outcomes). Plot showing MR
 IVW meta-analysis effect estimates (OR). OR above 1 indicate a tendency towards the morning chronotype and OR
 below OR indicate a tendency towards the evening chronotype. Each line represents CI and red dots identify
 associations that reach the Bonferroni-corrected significance threshold. ADHD, attention-deficit hyperactivity disorder;
 ASD, autism spectrum disorder; BD, bipolar disorder; CI, confidence intervals; IVs, instrumental variants (#GWS
 SNPs for the exposure (chronotype)); MDD, major depressive disorder.







Figure 2. MR scatter plot of chronotype (exposure) vs neuropsychiatric disorders risk (outcome). This plot 367 shows the effect size comparison (beta) for each instrumental variant used in the MR analysis. The x-axis indicates 368 effect estimate for each SNP on morning chronotype while the y-axis indicates the effect estimate for the SNP on 369 ASD (Figure 2A) and SZ (Figure 2B). Error bars at each point indicate the standard error for each IV in a single-370 variant MR analysis. The slopes from each coloured line represents the results from meta-analysis across multiple 371 MR methods performed and the slope represents the degree of association.

- 372
- 373
- 374
- 375
- 376

#### Causal effects of neuropsychiatric disorders on chronotype 377

378 Our results of two-sample MR analysis demonstrated a greater genetic risk for insomnia (OR = 0.95, CI = 0.92-0.95 and IVW P = 8.92x10<sup>-6</sup>) and SZ (OR = 0.88, CI = 0.82-0.94, IVW P = 5x10<sup>-</sup> 379 <sup>4</sup>) is causal for tendency towards the evening chronotype (**Figure 3**). We calculated causal 380 381 effect estimates using MR-PRESSO, MR Egger and the median-based estimate and by 382 comparing across methods. We found similar beta effect sizes albeit with wider confidence 383 intervals (Supplementary Table 5). Figure 4 shows that there is consistency across the various 384 MR methods performed for effect size and direction for the two statistically significant results, 385 insomnia (Figure 4a) and SZ (Figure 4b). We also performed IV outlier removal by using the 386 MR-PRESSO outlier test. The results indicated that 24 outliers for insomnia and 14 outliers for SZ were observed and subsequently these were removed from the MR analysis 387 388 (Supplementary Table 5), resulting in stronger associations identified between the significant 389 exposure-outcome pairs.

- 390
- 391
- 392





Figure 3. MR forest plot of neuropsychiatric disorder (exposure) vs. chronotype (outcome). Plot showing MR IVW
 meta-analysis effect estimates (OR). OR above 1 indicate a tendency towards the morning chronotype and OR
 below OR indicate a tendency towards the evening chronotype. Each line represents CI and red point colours identify
 associations that reach the Bonferroni-corrected significance threshold. ADHD, attention-deficit hyperactivity disorder;
 BD, bipolar disorder; CI, confidence intervals; IVs, instrumental variants (#GWS SNPs for the exposures (five
 neuropsychiatric disorders)); MDD, major depressive disorder.





408

Figure 4. MR scatter plot of neuropsychiatric disorders risk (exposure) vs chronotype (outcome). This plot shows the effect size comparison (beta) for each instrumental variant used in the MR analysis. The x-axis indicates the effect estimate for each SNP on insomnia (Figure 4a) and SZ (Figure 4b) while the y-axis indicates the effect estimate for the SNP on the morning chronotype. Error bars at each point indicate the standard error for each IV in a single-variant MR analysis. The slopes from each coloured line represents the results from meta-analysis across multiple MR methods performed and the slope represents the degree of association.

416

A similar pattern of results was observed for a number of sensitivity tests in either direction of MR analysis. Cochran's Q statistic found evidence for SNP effect sizes heterogeneity however we showed through consistency in the causal effect and direction, as predicted in sensitivity

420 tests, it is unlikely to introduce bias from horizontal pleiotropy. As we are using MR for complex traits, which consist of many SNPs with very small effect sizes across numerous genes and 421 422 biological functions, we expect that many of the SNPs used as IVs will have wide variability in 423 their estimated effect size. We also found no significant results from the MR Egger intercept test 424 (p > 0.05), suggesting that no bias due to horizontal pleiotropy was observed. This is also 425 supported by the individual SNP tests (leave-one-out analyses), where no individual SNP-426 exposure association was found to dominate the estimate of the causal effect (30). Full details 427 on the sensitivity tests of the bidirectional MR analyses are available in Supplementary Table 5.

428

The results from multi-trait MR also show good support for these findings. We assessed the causal effect of psychiatric disorders (BD, MDD and SZ) on chronotype using three MR analysis designs and found that the predicted effect sizes and standard errors correlated with those generated in the uni-trait MR analyses. Statistical significance also remained for the effect of SZ on chronotype and a number of outlier IVs were no longer removed, due to accounting for the bias introduced from BD and MDD (<u>Supplementary Table 6</u>).

435

We also compared the results of MR analysis with results from genetic correlation, generated using GWASatlas. We verified that similar results were obtained using genetic correlations and showed that the direction of effect is in line with our results, indicating that chronotype is negatively correlated with risk of all the neuropsychiatric disorders that we investigated using MR. A similar pattern was found where a significant genetic correlation was found between chronotype and ASD, MDD and SZ (Supplementary Figure 1).

442

Finally, in order to assess the effect of heterogeneity due to sample population variation, we calculated causal effects between chronotype and a mixed ancestry SZ sample (20% East

Asian + 80% European) and demonstrated that similar effect estimates were obtained by comparing the results from the European ancestry study (<u>Supplementary Table 4</u>).

- 447
- 448

### 449 MR analysis to assess the role of SNPs associated with changes in gene

### 450 expression as risk factors for neuropsychiatric disorders and chronotype

451 We analysed the effect of changes in gene expression on outcomes by performing two-sample 452 MR using beta effect estimates for IVs for gene expression from eQTL summary statistics and 453 extracting beta effect sizes for neuropsychiatric disorders and chronotype from GWAS data 454 (Supplementary Table 7). We used a Wald ratio to estimate causal effects of 36,530 eQTL-gene 455 pairs, based on the number of unique eQTL-gene pairs passing LD clumping that had a 456 statistically significant association in blood or brain tissue. Bonferroni correction was performed 457 by tissue specific thresholds (outlined in Supplementary Table 8) that were used to determine 458 the significance of the causal effects found through MR and revealed 175 significant causal 459 effects where an outcome was mediated through gene expression alterations. These results 460 were from 66 unique eQTLs across 161 unique genes (Supplementary Table 7).

461

462 We found a significant impact of gene expression alterations, mediated through eQTLs, in 463 numerous genes for all of the outcomes that we analysed (ASD: 10 genes, ADHD: 2, BD: 34, 464 Insomnia: 2, MDD: 2, SZ: 105 and chronotype: 20, Supplementary Table 8). We then used 465 colocalization, an established method used to provide complementary evidence to predict 466 causal relationships between gene expression and complex traits, and found that strong 467 evidence for a causal effect remained for twelve of these associations, with PP4 > 0.7 468 (Supplementary Table 7). Figure 5 shows these twelve eQTLs with a significant causal role in 469 neuropsychiatric disorders or chronotype. Supplementary Table 7 includes the effect estimates ( $\beta$ )

470 and statistical significance (P) measured for each instrumental variant in the original eQTL ( $\beta_{exp}$  and

471  $P_{exp}$ ) and GWAS ( $\beta_{out}$  and  $P_{out}$ ).

472

473

474

eQTL	Position	Gene	Tissue	β	Outcome	р
rs3751033	11:130916450	RP11-890B15.3	GTEx_hippocampus	1.+	SZ	2.9e-08
rs4766492	12:110491456	GPN3	GTEx_blood	1.	SZ	8.3e-13
rs3751033	11:130916450	SNX19	GTEx_hippocampus		SZ	2.9e-08
rs3751033	11:130916450	SNX19	GTEx_hypothalamus		sz	2.9e-08
rs968567	11:61828092	FADS2	GTEx_blood	•	BD	7.7e-07
rs4968646	17:63437960	CYB561	GTEx_cortex	•	Chronotype	1.1e-06
rs3743138	15:40288963	RP11-133K1.12	GTEx_blood	• 1	SZ	6.8e-09
rs7535162	1:243262387	SDCCAG8	GTEx_blood	•1	SZ	1e-06
rs17128077	14:54919316	GCH1	GTEx_blood	+ 11	SZ	1.4e-06
rs11979881	7:102902565	ARMC10	PSYCHencode	- I	Chronotype	4.4e-07
rs832190	3:63856953	THOC7	GTEx_hippocampus	+	sz	2.5e-10
rs79073127	2:48346756	FOXN2	GTEx_blood		SZ	1.4e-07

-0.4 -0.2 0.0 0.2

### 475

476

477 Figure 5. Forest plot for significant associations found from MR analysis and colocalization of the causal 478 effect of gene expression on chronotype or neuropsychiatric disorders. For each eQTL SNP, the beta ( $\beta$ ) represents 479 the effect size of gene expression alterations in the respective gene for the corresponding outcome and tissue. The point and 480 lines at each row represent the strength of effect and confidence intervals for each comparison. The vertical dashed line 481 represents beta = 0. Results with beta shaded in blue indicate that increased gene expression is associated with the increased 482 risk for neuropsychiatric disorders or increased tendency for the morning chronotype. Results with beta shaded in red 483 indicate that decreased gene expression is associated with increased risk for the phenotype. The p-value indicates 484 the strength of the effect on the outcome and the tissue column indicates the source of the eQTL. Each result passed 485 the MR test for causal effect estimate and colocalization for the same causal variant.

486

487 Six of twelve associations were blood-mediated and nine of twelve associations were for SZ. It

488 is notable that for the rs3751033 eQTL, we demonstrated a pleiotropic effect on *RP11-890B15* 

in the hippocampus and on *SNX19* in the hippocampus and hypothalamus (**Figure 5**).

490

491 As we were interested in finding supporting evidence for the causal effects of the twelve eQTLs,

492 we investigated if the associated eQTLs or genes have been previously linked to 493 neuropsychiatric disorders and/or chronotype. *CYB561* was not previously implicated in 494 chronotype. The result for rs4968646 and chronotype indicates that the causal effect at this

495 locus can be attributed to altered expression of CYB561 and not the TANC2 gene, which has 496 previously been reported to contain a SNP (rs17682747) that is in high LD with rs4968646 and 497 associated with chronotype (31). MR analysis provided further evidence for the association of 498 RP111-890B15, GPN3 and SNX19 with SZ, and FADS2 with BD. For rs4968646, rs17128077 499 and rs79073127, no published evidence was found for the association of an eQTL/gene with the 500 phenotype however results from PheWAS analysis, accessed through Open Targets Genetics, 501 show evidence of an association between numerous eQTLs and phenotypes (Supplementary 502 Table 9). Other eQTLs (rs3751033, rs4766492, rs832190, rs79073127) were previously 503 reported in the literature and MR provides further validation of these associations here.

504

505 The tool LDlink proved useful for investigating the phenotypes that were linked to a SNP by 506 proxy through a SNP in high LD. In most cases, the eQTL that was identified as causal through 507 MR analysis, for a given phenotype, was in high LD with a SNP that was previously linked to 508 that phenotype. For one eQTL (rs11979881 in ARMC10 which was linked to chronotype through 509 MR), neither the SNP or any SNP in high LD was previously linked to chronotype, indicating that 510 we may have identified new evidence for the link between the eQTL rs11989881 and gene 511 ARMC10. MR analysis also validates previously known links between sleep phenotypes and 512 neuropsychiatric disorders (FOXN2, GCH1, CYB561). More details on each of the findings and 513 a conclusion on the importance of each eQTL can be found in the Supplementary Table 9.

514

# 516 Discussion

517 We identified a causal effect of chronotype on risk for SZ and ASD, indicating that an individual 518 with the morning chronotype is at lower risk of developing either disorder. Jones et al. (2019) 519 and Sun et al. (2019) did previously report a causal effect of chronotype on SZ but that was 520 using a smaller sized SZ GWAS dataset (4, 32). Our finding of a causal effect of chronotype on 521 ASD has not been previously reported through MR but the direction of effect is consistent with 522 previous findings using measures of genetic correlation (14). In the opposite direction, we found 523 that insomnia and SZ both have a causal effect on chronotype, i.e., a genetic predisposition to 524 insomnia or SZ is causal for tendency towards the evening chronotype. The causal effect of 525 insomnia on chronotype is consistent with observations in individuals with insomnia i.e. those 526 with insomnia will typically wake and sleep later. These findings align widely with findings from 527 other studies on the relationship between chronotype and neuropsychiatric disorders, whereby 528 the evening chronotype is linked to increased risk and the morning chronotype is linked to lower 529 risk for neuropsychiatric disorders (6, 7, 33). We built upon the analyses performed in previous 530 studies by including the MR-PRESSO method, which allowed a new approach to identify and 531 correct for outliers contributing to horizontal pleiotropy. In addition, we employed the MR-532 STROBE method to deliver a clear and transparent MR analysis.

533

The validity of these results was tested through a number of sensitivity tests, to assess that the fundamental assumptions of MR were met: 1) Relevance assumption: The instrumental variables were selected based on p-value, as reported in the respective GWAS; 2) Independence assumption and 3) Exclusion restriction: The causal effect estimates were also created using MR-Egger, weighted median and mode-based methods (19, 20). The effect estimates yielded were similar to those in the IVW method. The MR-Egger intercept was also used and found no evidence that results deviated from 0, indicating little evidence for directional

genetic pleiotropy. Additionally, the multi-trait MR was used to account for confounding that may
exist due to other existing neuropsychiatric disorders (BD and MDD), with overlapping features.
These sensitivity tests gave sufficient evidence that MR analysis would produce reliable
estimates for causal effects.

545

546 The bidirectional relationship between SZ and chronotype can be interpreted as the morning 547 chronotype has a protective effect against SZ and, in the opposite direction, SZ can be a 548 contributing factor in someone having the evening chronotype. This bidirectional causal 549 relationship we identified between SZ and chronotype indicates that the evening chronotype can 550 be both a cause and effect of the SZ. This suggests that there may be a type of positive 551 feedback occurring whereby the disruption to sleep can initiate onset of SZ or perhaps make 552 symptoms worse. An individual with SZ may also then experience further sleep disruptions 553 which may lead to further disadvantageous symptoms of the disorder. The bidirectional 554 relationship may be due to the heterogenous and polygenic nature of SZ and sleep-based 555 phenotypes. Improved definition of sleep phenotypes and endophenotypes of SZ, and a better 556 understanding of their genetic basis, are required to further assess the complex relationship 557 between sleep and SZ.

558

559 Our second analysis was a unidirectional MR using eQTL and GWAS data, and was 560 combined with colocalization to investigate the causal effects for alterations in gene expression 561 on chronotype and six neuropsychiatric disorders. We found twelve instances where a unique 562 eQTL-gene association was causal for either chronotype, BD or SZ. In some cases, these data 563 support previously reported findings that have been identified through GWAS and PheWAS 564 analyses such as the association of SNX19 with SZ, which has been reported in multiple studies 565 (Supplementary Table 9). In other cases, our data provides new evidence for the effect of SNP-566 mediated gene expression on risk of chronotype and neuropsychiatric disorders. The genes that

567 have been identified may potentially inform on the biological mechanisms that could drive the 568 genetic component of these phenotypes, e.g. intracellular vesicle trafficking is mediated by 569 *SNX19* (34), and subsequently this process may be linked to SZ risk. Here we have used the 570 MR framework to understand in part how gene expression alterations influence neuropsychiatric 571 disorders and chronotype.

572

573 There are a number of strengths and weaknesses for each analysis. A major strength of the 574 study is the application of the MR-STROBE method, which provided valuable guidance on the 575 necessary information and additional analyses required to ensure robust analysis. For the first 576 study, the framework was useful for planning, selecting the sensitivity tests and selecting figures 577 and allowed us to perform analyses with reliable results through a proven method. We found 578 that when applied to the second study the MR-STROBE method needed some modifications to 579 be applicable in a multi-omic setting where additional methods such as colocalization are 580 typically integrated into the analysis. Nevertheless, MR-STROBE remained useful for identifying 581 the required study design components and methods to ensure that the second study was 582 robust.

583

584 In our first analysis, we estimated causal effects using multiple sensitivity analyses (MR-585 PRESSO, MR Egger and median based estimates) to test for horizontal pleiotropy or bias due 586 to potential confounders. We also made efforts to prevent bias due to sample heterogeneity by 587 using only European samples and performing LD pruning to prevent correlation between SNPs 588 used as genetic instruments. We utilised the MR-PRESSO outlier test to identify and remove 589 pleiotropic outliers and ensure robustness of our study design. We also compared the results to 590 those from studies of genetic correlation to validate that the directions of effect were consistent 591 with our findings.

592

593 There are a number of limitations to the first analysis. While we have demonstrated significant 594 evidence for a number of causal relationships, the biological basis of cause and effect remains 595 to be elucidated. This relates to the difficulty in interpreting the results of MR studies when we 596 use MR to study causal relationships of complex traits. When we perform MR using a single instrument with a clearly defined biological mechanism, we can design and guide treatments 597 598 using this as a target. However due to the nature of complex traits, where we are dealing with 599 many SNPs that have very low effect size, the biological impact of the individual SNPs is low 600 and MR can only be used for epidemiological purposes.

601

602 Another limitation to this analysis is that we perform MR using only European ancestry samples. 603 While two sample MR requires that the same underlying population is used, we believe that the 604 development of multi-ancestry MR methods will be important to fully utilise newer GWAS that 605 are beginning to include samples from numerous ancestry groups. Expansion of GWASs across 606 diverse populations will lead to sample sizes that are large enough to detect SNPs that can be 607 used as strong IVs in MR and identify new biological functions implicated in sleep and 608 neuropsychiatric disorders. Finally, it is important to consider that chronotype is a self-reported 609 measurement that may be biassed due to individual subjectivity and differences between 610 individuals in terms of their stage of life and environment (35).

611

The second analysis had a number of strengths including integrating functional data from PsychENCODE and GTEx. The integration of eQTL data allows us to determine that the effect of a SNP on the phenotype is mediated through gene expression alterations. The method also indicates the degree of effect size, which can be valuable for prioritising genes. Another strength is that we have extended to integrating colocalization analysis, meaning that we find evidence to support the causal effect found through MR by coupling with evidence for the same causal variant implicated in the phenotype and gene expression. The results of colocalization

619 demonstrated that, while a non-zero result can be obtained from MR, the result can lack 620 evidence for a causal effect.

621

622 Further limitations of this analysis are that we used eQTLs detected in a relatively small number 623 of brain samples and the decision to only include brain subregions that we deemed most 624 relevant to our studied phenotypes. One other limitation found in this case is the lack of 625 developmental stage-specific eQTLs, which may inform on varying effects of SNPs on gene 626 expression levels during various stages of development. The effect sizes are also small and 627 spread across numerous genes, meaning that feasibility for clinical application is limited. Finally, 628 it is surprising that we did not achieve more significant findings from PsychENCODE, which was 629 the largest source of eQTL data that we had available.

630

631 Overall, our MR analysis validated previous findings and provided new evidence for the 632 biological aetiology of our neuropsychiatric disorders, chronotype and their complex 633 relationship. We demonstrated that chronotype and neuropsychiatric disorders have a direct 634 causal effect on each other, and that chronotype and risk for neuropsychiatric disorders (BD and 635 SZ) are influenced by gene expression alterations in the blood and/or specific brain regions 636 (hippocampus, cortex and hypothalamus). We identify a number of genes that are implicated in 637 both chronotype and neuropsychiatric disorders that give important insight into the overlapping 638 biology that is known to exist between neuropsychiatric disorders and sleep phenotypes. Future 639 analyses may focus on diversifying the sources and types of GWAS and multi-omic data to 640 integrate data on additional sleep phenotypes, regulatory function and brain regions that may 641 mediate the links between neuropsychiatric disorders and chronotype. Integration of trans-eQTL 642 data may provide further insights into the genetic basis of these phenotypes. Follow-up studies 643 may also include a complete comparison to results from other methods that integrate 644 expression data which include TWAS and S-PrediXcan. Interventions such as light therapy,

645 which can manipulate an individual's sleep timing (36), are available to influence chronotype. Given our study findings that evening chronotype is causally associated with risk of NPDs, these 646 647 interventions may be useful to alter sleep timing towards the morning chronotype and reduce 648 risk of NPDs. 649 650 651 Funding This research was funded by Science Foundation Ireland (SFI) through the SFI 652 Centre for Research Training in Genomics Data Science under Grant number 18/CRT/6214. 653 654 Bioinformatics Resources The sources used in the literature search included GWAScatalog 655 (37, https://www.ebi.ac.uk/gwas/home), Open Targets Genetics (38, 656 https://genetics.opentargets.org), ClinVar (39, https://www.ncbi.nlm.nih.gov/clinvar), SNPedia (40, https://www.snpedia.com) and dbSNP (41, https://www.ncbi.nlm.nih.gov/projects/SNP). 657 658 659 Data and data sharing We deposited the full scripts for our MR analysis on GitHub 660 (Objective 1 available at shanecrinion/causal-inference and Objective 2 available at 661 shanecrinion/mendelian-randomisation-qtl). 662 663 **Conflict of Interest** The authors declare that they have no competing financial interests in 664 relation to the work described here. 665 666 667

668	References
669	1.Bray NJ, O'Donovan MC. The genetics of neuropsychiatric disorders. Brain and
670	Neuroscience Advances. 2018 Jan;2:239821281879927.
671	
672	
673	2.Alachkar A, Lee J, Asthana K, Vakil Monfared R, Chen J, Alhassen S, et al. The hidden link
674	between circadian entropy and mental health disorders. Translational Psychiatry. 2022 Jul
675	14;12(1).
676	
677	
678	3.Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J, Hammerschlag AR, et al. Genome-
679	wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional
680	pathways. Nature Genetics. 2019 Feb 25;51(3):394–403.
681	
682	
683	4.Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-wide
684	association analyses of chronotype in 697,828 individuals provides insights into circadian
685	rhythms. Nature Communications. 2019 Jan 29;10(1).
686	
687	
688	5.Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
689	contribute to understanding environmental determinants of disease?*. International Journal of
690	Epidemiology. 2003 Feb;32(1):1–22.
691	
692	
693	6.Carpena MX, Bonilla C, Matijasevich A, Martins-Silva T, Genro JP, Hutz MH, et al. Sleep-
694	related traits and attention-deficit/hyperactivity disorder comorbidity: shared genetic risk factors,
695	molecular mechanisms, and causal effects [Internet]. Cold Spring Harbor Laboratory; 2020 Sep
696	[cited 2023 Feb 11]. Available from: http://dx.doi.org/10.1101/2020.09.13.20193813
697	
698	
699	7.Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-
700	wide association study of more than 40,000 bipolar disorder cases provides new insights into
701	the underlying biology. Nature Genetics. 2021 May 17;53(6):817–29.

702	
703	
704	8.Dashti HS, Jones SE, Wood AR, Lane JM, van Hees VT, Wang H, et al. Genome-wide
705	association study identifies genetic loci for self-reported habitual sleep duration supported by
706 707	accelerometer-derived estimates. Nature Communications. 2019 Mar 7;10(1).
708	
709	9.Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in
710	causal relationships inferred from Mendelian randomization between complex traits and
711	diseases. Nature Genetics. 2018 Apr 23;50(5):693–8.
712	
713	
714	10.Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence
715	from Mendelian randomization and colocalization: Review and comparison of approaches. The
716	American Journal of Human Genetics. 2022 May;109(5):767–82.
717	
718	
719	11.Baird DA, Liu JZ, Zheng J, Sieberts SK, Perumal T, Elsworth B, et al. Identifying drug
720	targets for neurological and psychiatric disease via genetics and the brain transcriptome. PLOS
721	Genetics. 2021 Jan 8;17(1):e1009224.
722	
723	
724	12.Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ,
725	et al. Strengthening the reporting of observational studies in epidemiology using mendelian
726	randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021 Oct
727	26;375(2233):n2233.
728	
729	
730	13.Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the
731	first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics.
732	2018 Nov 26;51(1):63–75.
733	
/34 70-	
735	14. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of

common genetic risk variants for autism spectrum disorder. Nature Genetics. 2019 Feb 25;51(3):431-44. 15. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions [Internet]. Cold Spring Harbor Laboratory; 2018 Oct [cited 2023] Apr 12]. Available from: http://dx.doi.org/10.1101/433367 16.Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022 Apr 8;604(7906):502-8. 17.Burgess S, Butterworth A, Thompson SG. Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data. Genetic Epidemiology. 2013 Sep 20;37(7):658-65. 18.Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018 May 30;7. 19.Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology. 2015 Apr 1:44(2):512-25. 20.Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology. 2016 Apr 7;40(4):304–14. 

770	
771	21.Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
772	randomisation studies with summary data and a continuous outcome. Statistics in Medicine.
773	2015 May 7;34(21):2926–40.
774	
775	
776	22.Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, Minelli C, et al. Improving
777	the visualization, interpretation and analysis of two-sample summary data Mendelian
778	randomization via the Radial plot and Radial regression. International Journal of Epidemiology.
779	2018 Jun 28;47(4):1264–78.
780	
781	
782	23.Cardno AG, Owen MJ. Genetic Relationships Between Schizophrenia, Bipolar Disorder,
783	and Schizoaffective Disorder. Schizophrenia Bulletin. 2014 Feb 24;40(3):504–15.
784	
785	
786	24.Watanabe K, Stringer S, Frei O, Umićević Mirkov M, de Leeuw C, Polderman TJC, et al. A
787	global overview of pleiotropy and genetic architecture in complex traits. Nature Genetics. 2019
788	Aug 19;51(9):1339–48.
789	
790	
791	25.Aguet F, Anand S, Ardlie KG, Gabriel S, Getz GA, Graubert A, et al. The GTEx
792	Consortium atlas of genetic regulatory effects across human tissues. Science. 2020 Sep
793	11;369(6509):1318–30.
794	
795	
796	26.Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, et al. The
797	PsychENCODE project. Nature Neuroscience. 2015 Nov 25;18(12):1707–12.
798	
799	
800	27.Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for
801	Mendelian randomization. Statistical Methods in Medical Research. 2015 Aug 17;26(5):2333-
802	55.
803	

804	
805	28.Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary
806	data from GWAS and eQTL studies predicts complex trait gene targets. Nature Genetics. 2016
807	Mar 28;48(5):481–7.
808	
809	
810	29.Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
811	Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary
812	Statistics. PLoS Genetics. 2014 May 15;10(5):e1004383.
813	
814	
815	30.Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
816	Guidelines for performing Mendelian randomization investigations. Wellcome Open Research.
817	2020 Apr 28;4:186.
818	
819	
820	31.Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic
821	Functional Enrichment to Improve GWAS Power. The American Journal of Human Genetics.
822	2019 Jan;104(1):65–75.
823	
824	
825	32.Sun X, Liu B, Liu S, Wu DJH, Wang J, Qian Y, et al. Sleep disturbance and psychiatric
826	disorders: a bidirectional Mendelian randomisation study. Epidemiology and Psychiatric
827	Sciences. 2022;31.
828	
829	
830	33.O'Loughlin J, Casanova F, Jones SE, Hagenaars SP, Beaumont RN, Freathy RM, et al.
831	Using Mendelian Randomisation methods to understand whether diurnal preference is causally
832	related to mental health. Molecular Psychiatry. 2021 Jun 8;26(11):6305–16.
833	
834	
835	34.Harashima S ichi, Horiuchi T, Wang Y, Notkins AL, Seino Y, Inagaki N. Sorting nexin 19 regulates the
836	number of dense core vesicles in pancreatic $eta$ -cells. Journal of Diabetes Investigation. 2011 Jun
837	28;3(1):52–61.

838	
839	
840	35.Gentry NW, Ashbrook LH, Fu YH, Ptáček LJ. Human circadian variations. Journal of
841	Clinical Investigation. 2021 Aug 16;131(16).
842	
843	
844	36.Canazei M, Bassa D, Jimenez P, Papousek I, Fink A, Weiss E. Effects of an adjunctive,
845	chronotype-based light therapy in hospitalized patients with severe burnout symptoms - a pilot
846	study. Chronobiology International. 2019 May 9;36(7):993–1004.
847	
848	
849	37.Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, et al. The NHGRI-EBI GWAS
850	Catalog: knowledgebase and deposition resource. Nucleic acids research. 2023 Jan
851	6;51(D1):D977–85.
852	
853	
854	38.Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, et al. Open
855	Targets Genetics: systematic identification of trait-associated genes using large-scale genetics
856	and functional genomics. Nucleic Acids Research. 2020 Oct 12;49(D1):D1311–20.
857	
858	
859	39.Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar:
860	improving access to variant interpretations and supporting evidence. Nucleic Acids Research.
861	2017 Nov 20;46(D1):D1062–7.
862	
863	
864	40.Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annotation,
865	interpretation and analysis. Nucleic Acids Research. 2011 Dec 2;40(D1):D1308–12.
866	
867	
868	41.Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the
869	NCBI database of genetic variation. Nucleic Acids Research. 2001 Jan 1;29(1).
870	

